{"componentChunkName":"component---src-templates-topic-topic-tsx","path":"/topics/bells-palsy/","result":{"data":{"firstChapter":{"id":"4766eebb-2309-5052-95ac-c1caa9148c74","slug":"summary","fullItemName":"Summary","subChapters":[],"depth":1,"htmlHeader":"<!-- begin field 3a7724fa-77d4-46ef-82f2-8862069e22b2 --><h1>Bell's palsy: Summary</h1><!-- end field 3a7724fa-77d4-46ef-82f2-8862069e22b2 -->","htmlStringContent":"<!-- begin item d648d628-7991-4845-a643-56ca467091a0 --><!-- begin field bff78836-953a-4686-a393-26f6efd5844d --><ul><li>Bell's palsy is an acute, unilateral facial nerve weakness or paralysis of rapid onset (less than 72 hours) and unknown cause.<ul><li>Herpes simplex virus, varicella zoster virus, and autoimmunity may contribute to the development of Bell's palsy, but the significance of these factors remains unclear.</li></ul></li><li>Bell's palsy affects 20–30 people per 100,000 each year. It most common between 15 and 45 years of age.</li><li>Complications include eye injury, facial pain, dry mouth, intolerance to loud noises, abnormal facial muscle contraction during voluntary movements, and psychological sequelae.</li><li>A diagnosis of Bell's palsy can be made when no other medical condition is found to be causing facial weakness or paralysis. Symptoms include:<ul><li>Rapid onset (less than 72 hours).</li><li>Facial muscle weakness (almost always unilateral) involving the upper and lower parts of the face. This causes a reduction in movement on the affected side, often with drooping of the eyebrow and corner of the mouth and loss of the nasolabial fold.</li><li>Ear and postauricular region pain on the affected side. </li><li>Difficulty chewing, dry mouth, and changes in taste.</li><li>Incomplete eye closure, dry eye, eye pain, or excessive tearing.</li><li>Numbness or tingling of the cheek and/or mouth.</li><li>Speech articulation problems, drooling.</li><li>Hyperacusis.</li></ul></li><li>Features atypical of Bell's palsy require referral for exclusion of an alternative diagnosis.</li><li>To manage Bell’s palsy:<ul><li>The person should be advised to keep the affected eye lubricated by using lubricating eye drops during the day and ointment at night. The eye should be taped closed at bedtime using microporous tape, if the ability to close the eye at night is impaired.</li><li>For people presenting within 72 hours of the onset of symptoms, prescription of prednisolone should be considered.</li><li>Antiviral treatment alone is not recommended, but it may have a small benefit in combination with a corticosteroid; specialist advice is recommended if this is being considered.</li></ul></li><li>Urgent referral is required under certain circumstances, including:<ul><li>Worsening of existing neurologic findings, or new neurologic findings.</li><li>Features suggestive of an upper motor neurone cause.</li><li>Features suggestive of cancer. </li><li>Systemic or severe local infection.</li><li>Trauma.</li></ul></li><li>Referral to a facial nerve specialist should be arranged if there is doubt about the diagnosis or there is:<ul><li>No improvement after 3 weeks of treatment. </li><li>Incomplete recovery 5 months after the onset of initial symptoms. </li><li>Any atypical features. <strong> </strong></li></ul></li><li>Referral to an ophthalmologist is needed if the person has eye symptoms (for example pain, irritation, or itch).  </li><li>Referral for further support or counselling should be considered if there are emotional consequences of persistent facial paralysis or paresis.</li></ul><!-- end field bff78836-953a-4686-a393-26f6efd5844d --><!-- end item d648d628-7991-4845-a643-56ca467091a0 -->","topic":{"id":"6fbcd4fc-1e27-559d-a207-7d4c6e8a54c5","topicId":"9c711b5e-c5b5-4f3c-b945-03cdc7807c10","topicName":"Bell's palsy","slug":"bells-palsy","aliases":[],"chapters":[{"id":"4766eebb-2309-5052-95ac-c1caa9148c74","slug":"summary","fullItemName":"Summary","subChapters":[]},{"id":"db32d671-3f2b-5a87-b519-7669b8264c9a","slug":"have-i-got-the-right-topic","fullItemName":"Have I got the right topic?","subChapters":[]},{"id":"f0f94c71-8863-5e80-afaf-ce82a7ff02e6","slug":"how-up-to-date-is-this-topic","fullItemName":"How up-to-date is this topic?","subChapters":[{"id":"2d1a280f-83d3-5834-8106-967a1775e6fc","slug":"changes","fullItemName":"Changes"},{"id":"1aaff76b-872b-5b85-92e8-a5f0b5c67456","slug":"update","fullItemName":"Update"}]},{"id":"fc61bdf1-ca84-5251-917a-fbaab7117880","slug":"goals-outcome-measures","fullItemName":"Goals and outcome measures","subChapters":[{"id":"c98cd005-6000-5418-99a1-ac342ad3b4e7","slug":"goals","fullItemName":"Goals"},{"id":"876cef67-9108-5739-9141-704b04759856","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"ff255679-9bc9-5a91-a85c-2625d677c680","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"10d81db5-096a-5c90-b0ee-3de71dabf027","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"f1bb6854-fede-5e16-b78b-44afca38d202","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"e38894d6-3084-5df2-9413-00eb027d1163","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"7e6b973b-b704-56dc-a55c-af9fdc05661f","slug":"background-information","fullItemName":"Background information","subChapters":[{"id":"915bc3f0-4245-580a-9c92-09bd021d7cd5","slug":"definition","fullItemName":"Definition"},{"id":"3dea1016-6501-5565-a564-2fcc8ff4b4cc","slug":"causes","fullItemName":"Causes"},{"id":"f6fd8c55-4dda-56c3-803c-9b39e31756e4","slug":"prevalence","fullItemName":"Prevalence"},{"id":"89fcff44-16b1-5c34-934f-6f1e9fa581a3","slug":"complications","fullItemName":"Complications"},{"id":"ce4aa652-88c1-54de-9710-b2e99d125c14","slug":"prognosis","fullItemName":"Prognosis"}]},{"id":"750af3ec-c1d1-50ef-8c31-adbaa6bb1d66","slug":"diagnosis","fullItemName":"Diagnosis","subChapters":[{"id":"05b003ce-5eeb-5a69-90cb-06156a2d161a","slug":"diagnosis","fullItemName":"Diagnosis"},{"id":"5149e954-facb-51cd-933c-ca1a6a347e45","slug":"differential-diagnosis","fullItemName":"Differential diagnosis"}]},{"id":"585d604e-eaf7-502b-ac0a-b095aa5bbe2f","slug":"management","fullItemName":"Management","subChapters":[{"id":"580ab30d-9576-59c4-aeb3-9e8ab7cf50f6","slug":"management","fullItemName":"Scenario: Management"}]},{"id":"432dede6-8464-590b-a61f-3171fc8e7cd3","slug":"prescribing-information","fullItemName":"Prescribing information","subChapters":[{"id":"0658bd57-de66-5dc2-8f3e-306129a919cc","slug":"prescribing-corticosteroids","fullItemName":"Prescribing corticosteroids"}]},{"id":"678ae58e-9085-5f8f-8954-bf1b7cf37ec3","slug":"supporting-evidence","fullItemName":"Supporting evidence","subChapters":[]},{"id":"90857d48-d611-53bc-b3ea-5ed10d7969ad","slug":"how-this-topic-was-developed","fullItemName":"How this topic was developed","subChapters":[{"id":"02482d74-322e-5b12-91be-457763d1565f","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"f0e77799-ffea-5a5c-89ab-ab66837415c6","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"59a234a3-506d-5e44-80fc-95608abc0551","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"2f1ea24b-e581-527f-b00d-3edb42411a27","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"9860105b-6cd3-590e-8b47-75b5ae738fa6","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"142db3ba-6dda-5137-b241-8a8c353d1ebb","slug":"references","fullItemName":"References","subChapters":[]}]}},"topic":{"id":"6fbcd4fc-1e27-559d-a207-7d4c6e8a54c5","topicId":"9c711b5e-c5b5-4f3c-b945-03cdc7807c10","topicName":"Bell's palsy","slug":"bells-palsy","aliases":[],"topicSummary":"Bell's palsy is an acute, unilateral, idiopathic, facial nerve paralysis. The paralysis also affects the eyelids, causing an impairment of blinking.","lastRevised":"Last revised in May 2019","nextPlannedReviewBy":"2023-05-01T00:00:00+01:00","nextPlannedReviewByDateTime":"2023-04","nextPlannedReviewByDisplay":"April 2023","specialities":[{"id":"bb606678-e2cc-550b-bd11-bd7b8e7d05e1","name":"Ear, nose and throat","slug":"ear-nose-throat"},{"id":"08590215-7450-5fd4-bb09-b98865ce23ee","name":"Neurological","slug":"neurological"}],"chapters":[{"id":"4766eebb-2309-5052-95ac-c1caa9148c74","slug":"summary","fullItemName":"Summary","subChapters":[]},{"id":"db32d671-3f2b-5a87-b519-7669b8264c9a","slug":"have-i-got-the-right-topic","fullItemName":"Have I got the right topic?","subChapters":[]},{"id":"f0f94c71-8863-5e80-afaf-ce82a7ff02e6","slug":"how-up-to-date-is-this-topic","fullItemName":"How up-to-date is this topic?","subChapters":[{"id":"2d1a280f-83d3-5834-8106-967a1775e6fc","slug":"changes","fullItemName":"Changes"},{"id":"1aaff76b-872b-5b85-92e8-a5f0b5c67456","slug":"update","fullItemName":"Update"}]},{"id":"fc61bdf1-ca84-5251-917a-fbaab7117880","slug":"goals-outcome-measures","fullItemName":"Goals and outcome measures","subChapters":[{"id":"c98cd005-6000-5418-99a1-ac342ad3b4e7","slug":"goals","fullItemName":"Goals"},{"id":"876cef67-9108-5739-9141-704b04759856","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"ff255679-9bc9-5a91-a85c-2625d677c680","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"10d81db5-096a-5c90-b0ee-3de71dabf027","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"f1bb6854-fede-5e16-b78b-44afca38d202","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"e38894d6-3084-5df2-9413-00eb027d1163","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"7e6b973b-b704-56dc-a55c-af9fdc05661f","slug":"background-information","fullItemName":"Background information","subChapters":[{"id":"915bc3f0-4245-580a-9c92-09bd021d7cd5","slug":"definition","fullItemName":"Definition"},{"id":"3dea1016-6501-5565-a564-2fcc8ff4b4cc","slug":"causes","fullItemName":"Causes"},{"id":"f6fd8c55-4dda-56c3-803c-9b39e31756e4","slug":"prevalence","fullItemName":"Prevalence"},{"id":"89fcff44-16b1-5c34-934f-6f1e9fa581a3","slug":"complications","fullItemName":"Complications"},{"id":"ce4aa652-88c1-54de-9710-b2e99d125c14","slug":"prognosis","fullItemName":"Prognosis"}]},{"id":"750af3ec-c1d1-50ef-8c31-adbaa6bb1d66","slug":"diagnosis","fullItemName":"Diagnosis","subChapters":[{"id":"05b003ce-5eeb-5a69-90cb-06156a2d161a","slug":"diagnosis","fullItemName":"Diagnosis"},{"id":"5149e954-facb-51cd-933c-ca1a6a347e45","slug":"differential-diagnosis","fullItemName":"Differential diagnosis"}]},{"id":"585d604e-eaf7-502b-ac0a-b095aa5bbe2f","slug":"management","fullItemName":"Management","subChapters":[{"id":"580ab30d-9576-59c4-aeb3-9e8ab7cf50f6","slug":"management","fullItemName":"Scenario: Management"}]},{"id":"432dede6-8464-590b-a61f-3171fc8e7cd3","slug":"prescribing-information","fullItemName":"Prescribing information","subChapters":[{"id":"0658bd57-de66-5dc2-8f3e-306129a919cc","slug":"prescribing-corticosteroids","fullItemName":"Prescribing corticosteroids"}]},{"id":"678ae58e-9085-5f8f-8954-bf1b7cf37ec3","slug":"supporting-evidence","fullItemName":"Supporting evidence","subChapters":[]},{"id":"90857d48-d611-53bc-b3ea-5ed10d7969ad","slug":"how-this-topic-was-developed","fullItemName":"How this topic was developed","subChapters":[{"id":"02482d74-322e-5b12-91be-457763d1565f","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"f0e77799-ffea-5a5c-89ab-ab66837415c6","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"59a234a3-506d-5e44-80fc-95608abc0551","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"2f1ea24b-e581-527f-b00d-3edb42411a27","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"9860105b-6cd3-590e-8b47-75b5ae738fa6","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"142db3ba-6dda-5137-b241-8a8c353d1ebb","slug":"references","fullItemName":"References","subChapters":[]}]}},"pageContext":{"id":"6fbcd4fc-1e27-559d-a207-7d4c6e8a54c5"}},"staticQueryHashes":["3666801979"]}